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ABSTRACT
High-throughput screening (HTS) is an indispens-
able tool for drug (target) discovery that currently
lacks user-friendly software tools for the robust iden-
tification of putative hits from HTS experiments and
for the interpretation of these findings in the con-
text of systems biology. We developed HiTSeekR as
a one-stop solution for chemical compound screens,
siRNA knock-down and CRISPR/Cas9 knock-out
screens, as well as microRNA inhibitor and -mimics
screens. We chose three use cases that demonstrate
the potential of HiTSeekR to fully exploit HTS screen-
ing data in quite heterogeneous contexts to gener-
ate novel hypotheses for follow-up experiments: (i)
a genome-wide RNAi screen to uncover modulators
of TNF , (ii) a combined siRNA and miRNA mimics
screen on vorinostat resistance and (iii) a small com-
pound screen on KRAS synthetic lethality. HiTSeekR
is publicly available at http://hitseekr.compbio.sdu.
dk. It is the first approach to close the gap between
raw data processing, network enrichment and wet lab
target generation for various HTS screen types.
INTRODUCTION
High-throughput screening (HTS) is a versatile and pow-
erful technique for systematic bio-medical research. For-
merly used exclusively by pharmaceutical companies, more
and more academic institutions seek to extend the applica-
tion beyond screening for chemical compounds to screens
concerned with the systematic manipulation of gene or
microRNA (miRNA) expression. HTS is generally char-
acterized by a high degree of assay miniaturization and
robotic automation. This allows rapid screening of mi-
crotiter plates, each of which can hold up to 1536 experi-
ments. The result of an HTS experiment is a numeric read-
out of cellular response, e.g. to determine cell viability or
metabolic activity. It is acquired via absorbance, fluores-
cence, or luminescence, typically measured between two dif-
ferent conditions or for two different cell types (Figure 1A).
HTS data analysis is complicated and time-consuming.
For example, a differential human genome-wide RNAi
screen comparing two different cell-lines in triplicates re-
sults in ∼120 000 data points (experiments), which need
to be processed to identify significant biological signals.
HTS data suffers from experiment-specific signal variation
caused by, e.g. plate, batch, library and positional bias (1,2).
The robust identification of putative hits, i.e. samples with a
desired phenotype, thus crucially depends on choosing ap-
propriate data normalization routines. This poses a signif-
icant hurdle for the analysis of HTS data in general and
for secondary and comparative analyses in particular (3).
The few existing statistical tools do not provide support for
all of the different kinds of HTS data, and they lack adap-
tive user interfaces (see Supplementary Material for a re-
quirement analysis and an overview of the state of the art).
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Figure 1. (A) In robotic high-throughput screening, a large number of microtiter plates is screened successively to interrogate cells via suitable assays. This
is often done in a differential setup. Our example shows siRNA screens between two cell lines (yellow and green). The majority of siRNAs is lethal to both
cell lines, whereas some are specific and potentially of therapeutic interest. (B) Three types of high-throughput screens (HTS) are supported in HiTSeekR,
namely gene centered, microRNA (multiple target genes) and small compound screens (targeting single or multiple proteins). (C) HiTSeekR complements
the typical HTS work-flow for hit selection, where only the top fraction of hits are subjected to secondary screening (dashed green line), by proposing hits
based on a multi-faceted systems biology analysis (solid green line). This is facilitated through integrated resources such as Bioconductor packages (BC)
or external web services (WS) and allows, for example, to perform (D) de novo network enrichment as shown here for one of the application cases.
In the standard HTS work-flow, a secondary screen is per-
formed for hit confirmation, which, however, is limited to
themost promising hits for economical reasons. In this step,
false positive hits, including those caused by off target ef-
fects, are identified, and only fully validated hits are then
subjected to in-depth functional characterization. Here, the
major goal is the identification of the bio-molecular mech-
anisms underlying the emergence of the phenotype of inter-
est. A considerable disadvantage of this approach is that the
primary screening data are not fully utilized, since most of
themoderate hits are neglected.Moreover, the development
of complex diseases such as cancer is not centered around
individual genes but on molecular pathways controlled by
genes acting in concert.
MATERIALS AND METHODS
Normalization of raw signal
In addition to easily identifiable hits there are typically
many hits with moderate yet significant effect. The speci-
ficity and sensitivity for identifying these hits depends
largely on the ability to remove noise from the raw data. In
general, two types of normalization methods exist, namely
control based and plate based normalization.
Control based normalization. Control based normaliza-
tion methods rely on a series of wells containing negative
control samples that demonstrate little or no effect and
positive control samples that exhibit a strong effect. Con-
trol samples can be used as a reference point to measure
the relative effect observed in samples located on the same
plate as the controls. This allows for inter-plate comparisons
even if absolute values vary significantly between plates and
batches, since the control normalized values express the sig-
nal of the various plates as a percentage of effect strength.
The two most common control based normalization meth-
ods are implemented in HiTSeekR.
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Percentage of control (POC). Here, only a single control
type is needed to establish a reference point, i.e.
POC = xi
c¯
· 100
where c¯ corresponds to the controlmean and xi corresponds
to the sample value.
Normalized percentage inhibition (NPI). Here, two con-
trols establish an effect range that can be computed as a
percentage, i.e.
NPI = c¯+ − xi
c¯+ − c¯− · 100
where c¯− corresponds to the mean of the negative control
and c¯+ corresponds to the mean of the positive control, re-
spectively.
Plate based normalization. Control based normalization is
often considered inappropriate, since the number of con-
trol wells is typically kept small to reserve more space for
samples. Moreover, control wells are typically located on
the outer wells, where the signal is often strongly biased by
evaporation. Most importantly, control samples may occa-
sionally not perform as expected, e.g. in cell viability assays,
where negative controls may prove lethal for a particular
cell line or where a cell line may be resistant toward a nor-
mally lethal positive control (4). A viable alternative is plate
based normalization, which operates under the assumption
that the majority of reagents do not demonstrate any sig-
nificant effect. Consequently, most wells in a plate qual-
ify as negative controls, which largely increases the number
of wells contributing to a virtual reference point. A con-
trol reagent may show unexpected behavior in some sce-
narios, while the plate-based normalization is more robust
due to the large number of contributing samples (5). Plate
based normalization, however, is limited to primary screen-
ing. Follow-up screens are typically confirmation screens
of hits found in the primary screen, where this assumption
does not hold. Consequently, control wells are typically in-
cluded in primary screening evenwhen only plate based nor-
malization methods are considered. The control wells will
then be used at a later stage to compare the effect strength
between primary and secondary screening results. Finally,
screening libraries are sometimes not randomized but clus-
tered. In this case, it is quite likely that groups of wells
on a plate demonstrate comparable effects. Examples are
small compound libraries, where structurally similar com-
pounds are often grouped or siRNA libraries, where func-
tionally related reagents may be located on the same plate.
The most common plate based normalization methods are
implemented in HiTSeekR:
(Robust) z-score. The z-score expresses effect strength as
a function of the general variability of the data, i.e.
z− score = xi − x¯
SDp
where xi corresponds to the sample value, x¯ corresponds to
the plate mean and SDp corresponds to the standard devia-
tion (SD) of plate p. A disadvantage of this method is that it
considers all samples for computingmean and SD. Alterna-
tively, the robust z-score can be used, where mean and SD
are exchanged with median and median absolute deviation
(MAD), respectively. In z-score normalized data, the plate
mean is 0 and the SD is 1. This type of normalization cor-
rects for general differences in signal intensity and expresses
effect strength in dependence of the general signal variation,
thus allowing for inter-plate comparison.
B-score. A common problem in HTS are positional ef-
fects. These can be caused by, e.g. increased evaporation of
the outer wells or by a technical bias introduced in cell seed-
ing, where each row is typically supplied by a different tube.
The result of these effects is a signal bias that is inmost cases
row and column specific. Tomitigate this, Brideau et al. sug-
gest the B-score (6), which utilizes Tukey’s two way median
polish to obtain a signal estimate rijp that is corrected for
position specific bias xˆjip. It includes the estimated average
of the plate p as xˆp, the estimated offset of row i in plate p
as Rˆip and the estimated offset of column j in plate p as Cˆjp:
rijp = xijp − xˆijp
= xijp − (xˆp + Rˆip + Cˆjp)
Similar to the robust z-score, the B-score can be obtained
by dividing the corrected signal estimate by theMADof the
plate:
B− score = rijp
MADp
The B-score is ideally suited to deal with positional ef-
fects, but particularly in 96 well plates it may introduce
an additional bias in case of rows or columns that contain
many active samples.
Quality control
Quality control in HTS is imperative to identify batches or
individual plates that did not perform as expected, e.g. if
the transfection was inefficient or if the cell viability was
affected. Moreover, quality control helps to monitor time
dependent effects where the quality typically decreases with
each following plate, thus limiting the maximal batch size.
Several parameters of quality control can be investigated
visually, such as row and column means to check for po-
sitional effects, or scatter plots to investigate the signal dis-
tribution. Ideally, wells with positive and negative controls
are available on each plate. Two established measures that
assess howwell positive controls can be separated from neg-
ative controls are presented in the following.
Strictly standardizedmean difference. Acknowledging that
quality measures like the signal-to-noise and signal-to-
background ratio fail to capture the variability of the data
appropriately, Zhang et al. suggested a dimensionless pa-
rameter called Z-factor (7). It is defined as the ratio of the
difference between sample and control mean, and the dy-
namic range of the signal. This measure called Z-factor,
when comparing control values, is a widely used quality
measure in HTS. However, Zhang et al. have criticized it for
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a lack of solid statistical interpretation and proposed an al-
ternative score called strictly standardized mean difference
(SSMD) (8), which is defined as:
SSMD = μ1 − μ2√
σ 21 + σ 22
where 1 and 2 are the means and 1 and 2 the SDs of
two populations 1 and 2. It should be noted that popula-
tions here can refer to the comparison of two controls or a
sample and a control. Like the Z-factor, the SSMD captures
not only the difference, but also the variability of both pop-
ulations. In contrast to the Z-factor, however, the SSMD is
easier to interpret. An SSMD > 3 indicates that the mean
difference is at least three times the SD of the difference
of the two populations. Moreover, an SSMD > 3 indicates
that the probability that a value from the first population
is larger than a value of the second population is close to
1 (0.99865), adding a probability interpretation. Following
the three sigma-rule for significance, a SSMD of 3 is thus a
suitable cutoff for a pass/fail test.
Hit detection
The goal of HTS is to identify active samples or reagents in
a screen that show an effect. The threshold at which an ob-
served effect is considered significant depends on the vari-
ability of the data. Therefore, a common and straight for-
ward approach to detect hits is to define a threshold based
on ±k SDs or, to increase robustness, on ±k MADs. The
factor k is chosen by the user to control the number of hits
to be selected. A small k results in less stringent filtering and
is likely to include many false positives, while a large k will
lead to stringent filtering with and lead to many false nega-
tives. In reality, the choice of kmostly depends on economic
considerations, where asmany promising hits as possible are
included in a secondary confirmation screen. Therefore, the
false discovery rate (FDR) and its control via multiple test-
ing correction are widely ignored in primary screening.
SSMD for hit detection. The intuitive approaches of defin-
ing a window based on SD or MAD are often criticized for
being relative arbitrary. Moreover, these approaches are not
suited to fully utilize replicates. An intuitive alternative that
is often considered for HTS experiments with replicates is
thus the t-test, which can be used to assign a P-value to the
difference between sample and control replicates. However,
(9) demonstrated the t-test is in fact an inappropriate mea-
sure of effect strength, due to its dependence on the number
of available replicates. A suitable alternative for hit detec-
tion that separates the effect size of the impact of the num-
ber of replicate samples, is the SSMD score described above.
Bayesian hit detection. The hit discovery methods pre-
sented so far can be used to assess and rank the activity
of all samples in a screen. A common disadvantage is that
the FDR is unknown but expected to be inflated, since a
large number of samples are tested independently. More-
over, variation between plates and batches is only taken into
account on a per plate basis. While this strategy is generally
appropriate, it might lead to misleading results if individual
plates contain clusters of active samples (10), therefore pro-
pose an alternative hit discovery based on aBayesianmodel.
One of the main advantages of this method is that it calcu-
lates effect strength per plate while borrowing information
from the entire experiment.Moreover, this model maintains
a balance between contributions of sample wells and con-
trol wells. In practice, the experiment-wide information is
used to calculate the priors for the model, while the actual
likelihood is calculated per plate. Another major advantage
of this method is that it allows one to effectively control the
FDR via multiple testing correction, e.g. using the method
of Benjamini–Hochberg. Bayesian hit detection thus offers
a statistically motivated alternative for defining a threshold
for hit detection. The method presented here is more robust
to plate-specific signal bias due to its ability to utilize in-
formation of the entire experiment or batch, yet it does not
account for positional effects. Similar to control based nor-
malization methods, its effectiveness depends crucially on
the reliability of controls. Pooling the variance of negative
controls across plates, however, allows for this method to
be used even if relatively few negative control wells are in-
cluded. This is of particular importance for 96 well plates,
where typically only very few controls are available. The re-
sult of hit discovery in RNAi or CRISPR/Cas9 screens is a
list of genes that are associated with a particular phenotype.
In contrast, miRNA inhibitor or mimics screens require a
list of target genes.
microRNA target resources. The predictions of various
miRNA tools are available through the Bioconductor pack-
age RmiR, including predicted targets from mirbase (11),
targetScan (12), miRanda (13), miRDB (14) and PicTar
(15), as well as experimentally validated targets from tar-
base (16). In addition, we created a database of human
miRNA targets using the tool RNAhybrid (17,18). RNAhy-
brid predicts miRNA target interactions via the free bind-
ing energy. The advantage of this database, named RNAhy-
brid hsa, is that each miRNA target interaction is associ-
ated with a P-value. This allows for controlling the speci-
ficity of the target prediction and for keeping the num-
ber of false-positive predictions in a reasonable range. The
target prediction was run against human 3’UTRs derived
from human/mouse/rat multiz alignments from the UCSC
Genome Browser (19). Target sites were required to have a
seed match with the miRNA at miRNA positions 2 to 7,
and no G:U base pairs in the seed were allowed. P-values
were calculated from miRNA-specific binding energy dis-
tributions and normalized for target sequence length. Fi-
nally, we also integrated two miRNA target resources as
web services, namely a more up-to-date version of tarbase
providing experimentally validated targets and a prediction
method called micro-T-CDS (20).
Drug target resources. HiTSeekR utilizes the STITCH
databases (21) (v. 4.0 downloaded on 26/03/2015) to map
small compounds to prospective target genes (proteins).
The interactions in STITCH come with a score that can be
used to filter for high-confidence target genes. STITCH is
the ideal choice for HiTSeekR since it integrates relevant
databases in the field. Similar to miRNA target resources
introduced in the previous chapter, STITCH enables users
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to create a list of target genes that can be subjected to down-
stream analysis as described in the following section.
Functional enrichment analysis
HiTSeekR offers three powerful methods for interpreting
the results on the system biology level:
1. Gene Set Overrepresentation Analysis (GSOA):
Databases such as Reactome (22) link sets of genes
to functional categories and are used in GSOA. The
hypergeometric test is used to calculate a probability
for observing a given overlap between the genes in
the hit list and pre-defined functional gene sets. The
hypergeometric distribution in case of HTS data is
based on the number of potential target genes in the
screen (universe size) and the number of success states
(hits). Overrepresentation analysis identifies gene sets
for which significantly more genes are found to be hits
than would be expected by chance.
2. Gene Set Enrichment Analysis (GSEA): In GSOA anal-
ysis, only the membership of a hit gene in a gene set is
considered. In contrast, GSEA takes the rank of a all
genes of a set into account and relies on permutations to
assess significance (23).
3. Network Enrichment Analysis (NEA): The results of
GSEA as well as GSOA depend crucially on the selec-
tion of the a priori defined gene sets. In contrast, net-
work enrichment analysis utilizes biological networks
such as BioGrid (24) or I2D (25) that consist of ex-
perimentally validated or predicted interactions between
genes and/or proteins. This allows for functional path-
ways or functionally related gene sets to be discovered de
novo through dedicated methods such as those provided
by KeyPathwayMiner (26).
The first two are performed using the HTSAnalyzeR R
package (27), which uses KEGG (28) and Gene Ontology
(29) as sources of gene set annotations. However, since the
bioconductor R package for KEGG is outdated, we have
extended the HTSAnalyzeR package to also include Reac-
tomeDB (22) via its bioconductor R package.
To provide de novo network enrichment, HiTSeekR inte-
grates KeyPathwayMiner (26) through a RESTful web ser-
vice API. Therefore, HiTSeekR creates an indicator matrix
with one column (one case), and one row for each gene of
the hit list. HiTSeekR now uses KeyPathwayMiner’s INES
function to query a maximal connected sub-network cov-
ering only genes from the hit list allowing for a user-given
number (K) of exceptions (genes not in the hit list). As HiT-
SeekR utilizes the KeyPathwayMiner web service, pressing
the start analysis button will trigger a KeyPathwayMiner
run remotely. The user may either wait (up to 1 min) for the
results or continue to work with HiTSeekR until the analy-
sis is finished.
RESULTS
The lack of a user-friendly solution forHTS raw data analy-
sis and the untapped potential of systems biology in the field
motivated us to develop HiTSeekR, the first comprehensive
tool to offer guided analyses for all major screen types, in-
cluding small compound screens, RNAi knock-down and
CRISPR/Cas9 knock-out screens, as well as miRNA in-
hibitor and mimics screens (Figure 1B). HiTSeekR, which
is available at http://hitseekr.compbio.sdu.dk, complements
the classical work-flow of HTS through integrating various
systems biology methods for hypothesis generation (Figure
1C and D). The individual steps of this work-flow are de-
scribed below.
Data import
HiTSeekR facilitates HTS data analysis in a user friendly
and interactive web interface built with R shiny (http://
shiny.rstudio.com/). The use of R in the back end provides
us with powerful framework for statistical analysis as well
as visualization. The general work-flow of HiTSeekR be-
gins with the import of HTS raw data. Here, HiTSeekR is
flexible with respect to the format of the input data and al-
lows users to map columns to the properties required for
analysis. Moreover, HiTSeekR supports mapping of the
most common types of identifiers. Existing screening data
already available through the PubChem assay repository
https://pubchem.ncbi.nlm.nih.gov/ can be accessed directly
through the corresponding identifier. Note that imported
data are only saved transiently during the analysis and will
be deleted when the session expires.
Quality control
Subsequent to the data import, various plots are generated
to point the user to potential quality issues that need to
be taken into account for further analysis (Figure 2). This
includes plots concerned with the signal spread across dif-
ferent plates, the correlation of replicates, the performance
of control samples, as well as row- or column-effect typi-
cally caused through evaporation or clogging. In this way,
the user gains knowledge about the experiment-specific bias
allowing an educated choice for the following data normal-
ization strategy.
Hit discovery
Hit discovery is often the end-point of HTS analysis. Here,
samples exhibiting the strongest effect after normalization
are reported to the user. First, the user may select a number
of readouts and/or experiments found in the data for the
analysis. HiTSeekR supports various state-of-the-art nor-
malization methods and is thus able to address experimen-
tal bias appropriately.
A normalization method should be selected based on
the findings of the quality control step, i.e. a plate-based
method for primary screens in which the majority of the
samples do not show an effect or a control-based method
otherwise. For the former, users can choose between the (ro-
bust) z-score normalization or, if positional effects are evi-
dent, the B-score normalization. For the latter, users should
choose percentage of control if only one type of control is
given (negative or positive control) or normalized percent-
age inhibition if both a robust negative and positive control
are available. As is customary in the field, a fixed cutoff can
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Figure 2. HiTSeekR produces a series of plots for quality control. (A) Box plots of all plates and replicates. (B) Replicate correlation plot including a
linear regression (black line) with corresponding R2 correlation factor. The grey line indicates the identity. (C) Signal spread of the various controls across
all plates. The positive controls rela and tnfr1 are more robust than the negative controls sicon and lrp5. (D) Control separability measured by SSMD.
Here, the separability between the negative control lrp5 and the other controls is shown. The red area indicates bad separability and the orange area good
separability. An SSMD outside of the orange area indicates excellent separability. (E) Plate signal is centered by the mean and subsequently column means
are plotted across all plates and replicates to indicate positional effects typically evident by a u-shape.
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be chosen based on the distribution of the (normalized) sig-
nal. Each of these normalization methods is applied to the
individual plates and is thus not affected by batch effects
or differences between experiments. If both robust negative
controls and replicates are part of the screen, users are en-
couraged to apply the Bayesian normalization method (4).
Here, the normalization is applied to each individual read-
out in an experiment. This method combines experiment-
wide (negative controls) and plate-based information and
is the only method implemented in HiTSeekR that allows
controlling the false discovery rate.
Functional enrichment analysis
To better exploit primary screening data, computational
systems biology may identify affected molecular mecha-
nisms based on the molecular interplay of strong and/or
moderate hits. Gene silencing screens like RNAi or
CRISPR/Cas9 provide a list of hit genes that can be directly
subjected to further analysis. HiTSeekR supports GSOA,
GSEA (23), as well as de novo network enrichment anal-
ysis (26). While the former two are suitable for implicat-
ing knownmolecular and biological functions in the experi-
mental results, the latter can be used to identify novelmodu-
lators and functional units from large biological interaction
networks.
miRNA targets
A relatively new use case of HTS technology involves func-
tional analysis of miRNAs, which operate as key regulators
of biological processes by inhibiting the translation of up to
hundreds of genes. Consequently, system-level effects of in-
hibiting or mimicking a miRNA can only be understood
through interrogating the function of the affected genes.
Interactions between miRNAs and their target genes are
available through a number of experimental and predictive
databases, many of which have been included in HiTSeekR.
While lists of these target genes can be subjected to regular
systems biology analysis, previous studies indicate that this
may lead to erroneous results (30,31). We consider the issue
that a gene might be (predicted to be) targeted by several
miRNAs, possibly including a large number of miRNAs
that did not have an effect in the assay used in the exper-
iment. To mitigate this, we thus calculate, for each potential
target gene, a P-value for the enrichment of miRNAs hits
that (are predicted to) target a gene, compared to howmany
miRNAs in total (including effectors and non-effectors) are
predicted to target the gene. More formally, we would like
to calculate the probability that a target gene is targeted by
kmiRNAs, where k is the number of miRNAs in the hit list
that target this gene. To compute this probability, we use a
hypergeometric test. Consider an experimentwherewe draw
k successes from a population of sizeN in n draws, given that
there are K success states in the population:
P(X = k) =
(K
k
)(N−K
n−k
)
(N
n
)
Similarly, we use this to calculate the probability that k
out of n miRNAs target a particular gene given that this
gene is predicted as a target for K out of N total miRNAs.
Since we are interested in the probability of observing ≥k
miRNAs that target a particular gene, we can calculate the
cumulative probability as
P(X ≥ k) =
n∑
i=k
(K
i
)(N−K
n−i
)
(N
n
)
Since miRNAs from the same miRNA family will gener-
ally be predicted to target the same or largely overlapping
sets of genes, we restrict the calculation of target gene ef-
fect specificity to one representative of each miRNA fam-
ily. Genes with a low probability (P-value) are found more
frequently as targets in the miRNA hit list than we would
expect by chance and are thus important candidates after
multiple testing correction with the method of Benjamini
and Hochberg (32).
Drug targets
Small compound screening is the traditional use case of
HTS and aims at identifying drugs that typically influence
cellular function through targeting one or several proteins.
Although several million drug target interactions have al-
ready been collected in public databases such as STITCH
(21), a joint systems biology analysis of active compounds
in a screen is not common. HiTSeekRmitigates this by inte-
grating the STITCH database to perform functional analy-
sis and network enrichment on the target genes. In this way,
HiTSeekR enables researchers to identify drug sets address-
ing molecular functions or pathways responsible for a cer-
tain phenotype rather than focusing on individual genes.
Application cases
We demonstrate how HiTSeekR uniquely enables novel ap-
plications by studying three different kinds of publicly avail-
able HTS data sets that have been embedded in HiTSeekR
and that are briefly described in the following. The full set
of parameters are listed in Supplementary Tables S6–S9.
A genome-wide RNA interference screen identifies caspase
4 as a factor required for tumor necrosis factor alpha sig-
naling. The first example is a genome-wide RNAi screen
aimed at identifying modulators of tumor necrosis factor
alpha (TNF) (33), which is implicated in inflammatory dis-
eases and cancer. Here, we compare different normalization
strategies (Supplementary Figure S1) and go far beyond the
results of the original study by applying de novo network en-
richment analysis to evaluate the results of this screen in a
wider biological context. The individual steps of this anal-
ysis are described in full detail in the Supplementary Ma-
terial. As a result, HitSeekR implicates PHC2, a gene with
unknown function, to be a TNF modulator through its
connection to the NF-B pathway member CSNK2B (Fig-
ure 1D). In addition, we found several genes not directly hit
in the screen, such as GRB2 or RNF2 (Supplementary Fig-
ure S2 and S3), which are surrounded by several hit genes in
the interaction network. Consequently, these are interesting
candidates for follow-up studies (guilt-by-association prin-
ciple) that are neglected by existing HTS analysis pipelines.
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Genome-wide functional genomics analysis for genes regulat-
ing sensitivity to vorinostat. Falkenberg et al. performed
a genome-wide RNAi synthetic lethal drug screen to iden-
tify vorinostat sensitivity genes in human colon cancer cells
(34). In addition, Falkenberg et al. included a genome-wide
miRNA mimics screen under identical assay conditions.
Vorinostat is a histone deacetylase inhibitor used in can-
cer treatment. It was observed that the drug is quite ef-
fective in some patients whereas other patients do not re-
spond to therapy, raising the question what factors can ex-
plain the lack of a response against vorinostat in cancer.
While we focus on the miRNA mimics screen as an exam-
ple, the combination of a RNAi and miRNA screens of-
fers a unique opportunity to study if the observed effect at-
tributed to miRNA hits can partially be explained by indi-
vidual target genes. Both screens were split into a plus and
a minus drug arm, where the minus arm served to identify
genes that were lethal by knockdown alone via DAPI stain-
ing. On the plus drug arm, a cell viability assay was used
to assess rapid cell death, while a complementary caspase
activity readout served to assess apoptosis, i.e. slower cell
death. The raw data of the primary siRNA screen (Pub-
Chem AID 743454) and the miRNA mimics screen (Pub-
Chem AID 743456) can be downloaded directly into HiT-
SeekR and are also included as example data. Using the
miRNA screen, we performed de novo network enrichment
analysis based on 61 miRNA hits (5 caspase activity and
56 cell viability hits) and 442 putative target genes. In the
union graph built from the top 20 solutions (Supplemen-
tary Figure S4), SF3A1 was a prominent gene with a node
degree of eight. It is targeted directly by two different miR-
NAs, namely hsa-miR-497-5p and hsa-miR-15a-5p. Anal-
ysis of the RNAi screen reveals that SF3A1 as well as the
related gene SF3A3 are indeed moderate suppressors (with
a z-score of −3.3 and −3.6, respectively). They would not
have been considered for secondary screening without the
additional evidence uncovered by systems biology analysis,
and illustrate the power of network enrichment integration
withHTS data analysis. The individual steps of this analysis
are also shown in a video screencast available through the
HiTSeekR website.
KRAS synthetic lethal drug screen. A synthetic lethal drug
screen was downloaded from ChemBank with the acces-
sion ID 1004158. KRAS is a major oncogene and synthetic
lethal targets of KRAS have therefore been studied in the
past. Here, we analyze a systematic screen of 3947 small
compounds in the cell line HKE3, a model system for colon
cancer. Since no quality issues were observed, we used z-
score with standard deviation and a margin of 3 to extract
80 hits. Subsequently, we determined putative drug targets
using the STITCH database and a STITCH score thresh-
old of 500. The resulting 5128 compound–gene interactions
were analyzed on the systems biology level. Non surpris-
ingly, gene set analysis revealed “Pathways in Cancer” to be
the most significantly enriched pathway (adjusted P-value
1.02e-29). Most interestingly, de novo network enrichment
analysis yielded a single solution (Supplementary Figure
S5) that revealed frequent interactions of hit compounds
with cycline-dependent kinases such as CDK2 or CDK6
as well as glycogen synthase kinase 3 beta (GSK3B), both
of which are synthetic lethal interactions previously estab-
lished in the literature (35,36).
DISCUSSION
HiTSeekR is the first platform for integrated raw data and
systems biomedicine analysis. It strives to follow the reactive
design principle, which allows for a responsive and intuitive
user interface, where changes to input parameters trigger an
immediate update of the results. The user is guided in each
step of the analysis and can consult additional documen-
tation including a tutorial and video screencast. Each of
the above results can be obtained from the raw data within
15–30 min using HiTSeekR. It is the first comprehensive
tool that can be used to analyze HTS data in quite hetero-
geneous contexts down to the systems biology level. This
enables users to generate suitable hypotheses for follow-up
experiments efficiently.
The majority of screening data is often neglected in fa-
vor of a few of hits that are selected for in-depth functional
characterization. We acknowledge that resources are lim-
ited but propose that hit selection should not be limited
to the strongest effectors. Computational systems biology
methods can be used to identify molecular mechanisms af-
fected in the experiment more effectively on the basis of the
entire data set. Here, key mechanisms may only be iden-
tifiable through moderate hits, which would be neglected
in a classical analysis but are promoted for further studies
through such a systematic analysis. The aim of HiTSeekR
is thus to enable more widespread use of systems biology
methodology in the HTS community by offering a unified
and easily accessible processing platform. The results of ex-
tremely costly primary screening experiments may therefore
be better utilized. In addition, the systematic analysis serves
as an additional in silico filter for false positives. It is less
likely that many genes of a pathway (compared to single
genes) represent hits due to off target effects or measure-
ment errors. Most importantly, pathways are more likely to
unravel indications for systems biology events and alterna-
tive molecular signaling cascades behind complex diseases.
We demonstrated the potential of this strategy for the first
application case, an RNAi screen aimed at identifying mod-
ulators of TNFalpha, which did not include a systems biol-
ogy analysis in the original publication.With HiTSeekRwe
could perform GSOA and GSEA, which implicated RNA
polymerase II and ribosomal activity. Both processes are re-
lated to NFB signaling. These results are also supported
by de novo network enrichment, which identified a subnet-
work consisting ofDNApolymerase II subunits (results not
shown). Our findings are based on strong andmoderate hits
alike and allow for a hypothesis driven selection of samples
for follow-up experiments.
HiTSeekR is the first HTS analysis tool to accommodate
miRNA inhibitor or mimics screens. In order to perform
systems biology analysis on this type of screen, we annotate
miRNAs with corresponding target genes. The identifica-
tion of target genes also enables comparison between clas-
sical RNAi and miRNA screens as we demonstrate for our
second application case, in which both types of screen are
included but were only analyzed separately. We used HiT-
SeekR to identify miRNA target genes such as SF3A1 (see
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online screencast), which can be confirmed in the RNAi
screen where they are also hit.
Both, the experimental validation of miRNA target in-
teractions and the computational prediction ofmiRNA tar-
gets are active fields of research and the accuracy of exist-
ing methods (both in terms of false positives and false nega-
tives) is controversial.We included a variety of methods and
resources inHiTSeekR to acknowledge this fact and plan to
implement a mechanism that allows users to upload custom
miRNA target annotation files. In general, we note that our
selection of tools, methods and resources is not based on a
comparative evaluation and does consequently not neces-
sarily include the best performing options.
While powerful, the potential of the systems biology
driven analysis in HiTSeekR is ultimately limited by the
quality of database annotations and thus no substitute
for confirmatory screens. In particular the prediction of
miRNA and drug targets is challenging due to a presum-
ably high false positive rate, where, for instance, genes are
counted as targets even if they are not actually expressed in
a particular tissue. The results of HTS analysis in general
have to be considered carefully, since in vitro results can of-
ten not be confirmed in vivo (37).
In addition to proficient tools for data analysis, the HTS
community also depends on sample management systems
that can handle the large number of samples regularly cre-
ated during the robotic screening. To this end, several tools
exist, such as Screensaver (38), OpenBIS (39), Mscreen
(40) and SAVANAH(http://nanocan.github.io/SAVANAH,
manuscript in preparation). Currently, screening data have
to be exported from these tools and uploaded to HiTSeekR
or other HTS analysis tools for analysis. We thus plan im-
plementing a mechanism that allows direct export from
such applications to HiTSeekR in the future.
CONCLUSION
HiTSeekR paves the way for unique systems biomedicine
analysis of miRNA as well as small compound screens
through directly predicting target genes. Moreover, the
seamless integration of additional resources, such as DI-
ANA miRPath (41) or miRCancer (42), as well as func-
tional enrichment analysis based on gene sets and de novo
network enrichment is ideally suited to utilize HTS data
more effectively in the research of complex diseases.
In conclusion,HiTSeekR closes the gap between rawdata
processing, functional enrichment and wet lab target gen-
eration for various HTS screen types. Most importantly,
HiTSeekR may increase biological relevance of the selected
HTS targets using systems biology methodology.
ENDNOTES
http://chembank.broadinstitute.org/assays/view-assay.
htm?id=1004158 (last access 07/12/2015).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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